Soleno Therapeutics (SLNO) Change in Receivables (2013 - 2026)

Soleno Therapeutics' (SLNO) quarterly Change in Receivables came in at $18.9 million in Q1 2026, up 600.63% on a QoQ basis from $2.7 million in Q4 2025.

Soleno Therapeutics (SLNO) Change in Receivables (2013 - 2026) Analysis & Trends

Soleno Therapeutics (SLNO) has 7 years of Change in Receivables data on file, last reported at $18.9 million in Q1 2026.

  • On a quarterly basis, Change in Receivables changed N/A year-over-year to $18.9 million in Q1 2026; TTM through Mar 2026 was $47.1 million, a 1571400.0% increase from a year earlier, with the FY2025 full-year figure at $28.2 million, changed N/A from the prior year.
  • Change in Receivables for Q1 2026 stood at $18.9 million, up from $2.7 million in the prior quarter.
  • Over the last five years, Change in Receivables for SLNO reached as high as $24.6 million in Q2 2025 and fell as low as $882000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 75.30 Mn
4 NuCana 279.75 Bn 279.75 Bn - 2.84 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -39.80 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -1.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Soleno Therapeutics 874.25 Mn 618.67 Mn 93.41 Mn 18.93 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 18.93 Mn
Mar 31, 2026 18.93 Mn
Dec 31, 2025 2.70 Mn
Dec 31, 2025 2.70 Mn
Sep 30, 2025 882,000.00
Sep 30, 2025 882,000.00
Jun 30, 2025 24.62 Mn
Jun 30, 2025 24.62 Mn
Sep 30, 2017 -3,000.00
Sep 30, 2017 -3,000.00
Jun 30, 2017 23,000.00
Jun 30, 2017 23,000.00
Mar 31, 2017 -23,000.00
Mar 31, 2017 -23,000.00
Dec 31, 2016 -22,790.00
Dec 31, 2016 -22,790.00
Sep 30, 2016 -2,000.00
Sep 30, 2016 -2,000.00
Jun 30, 2016 -29,000.00
Jun 30, 2016 -29,000.00